Trump Influences Ozempic Pricing Deal

Novo Nordisk has reached a pricing agreement influencing the costs of its diabetes and obesity medications, Ozempic and Wegovy, potentially benefiting millions. This development comes as former President Donald Trump finalized a $35 billion arrangement allowing Medicare to cover these drugs, impacting the national debt. ABC's David Muir highlighted the deal, surprising viewers with its implications for healthcare and government spending.